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g.2013.1Abstract Background: Organic acid disorders are a heterogeneous group of inborn errors of
metabolism, in which organic acids accumulate in the body. They have high prevalence in Egypt
because of a high rate of consanguineous marriages. Here we report our experience with the
diagnostic evaluation of patients with organic acidemias as well as several other inborn errors of
metabolism (IEMs) by liquid chromatography–tandem mass spectrometry (LC/MS–MS), gas-chro-
matography mass spectrometry (GC/MS) and by isocratic cation exchange ‘‘high-performance
liquid-chromatography’’ (HPLC) to evaluate the use of HPLC method for disease-associated
metabolite screening.
Patients and methods: In this study, we screened 86 suspected Egyptians patients with organic
acid disorders by LC/MS–MS, GC/MS and by HPLC aged from 3 days to 12 years old. Data
obtained from the three methods were statistically analyzed to evaluate the speciﬁcity and sensitivity
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70 D.A. Ghoraba et al.organic acid disorders. Moreover, 17 urine samples were collected from patients with several other
IEMs to evaluate the efﬁciency of HPLC in detecting abnormal metabolites in urine samples.
Results: The screening results showed that diagnostic efﬁciencies were varied among the three
methods, HPLC showing a higher sensitivity of detecting normal urine as well as a highly satisfac-
tory extent for the detection of different metabolic disorders. In addition, some typical urinary
HPLC chromatograms of different metabolic disorders were presented to help the investigator
who is going to start an organic aciduria screening program by HPLC to be familiar with various
patterns.
Conclusion: This study has indicated that HPLC is an easy applicable and useful technique for
the initial screening of organic acid disorders and many other disease associated metabolites.
 2014 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
Organic acids comprise key metabolites of almost all pathways
of intermediary metabolism as well as exogenous compounds
[1]. Organic acid disorders (acidurias/acidemias) are an impor-
tant class of hereditary autosomal recessive diseases due to
gene defects in coding speciﬁc enzymes that are involved in
the metabolism of amino acids or organic acids. This results
in accumulation of organic acids in urine and, to a lesser ex-
tent, in other body ﬂuids [2,3]. Therefore, comprehensive anal-
ysis of organic acids in body ﬂuids has the potential of yielding
information on the pathophysiological status of affected indi-
viduals [1,4]. Patients with organic acidurias frequently present
with acute symptoms early in life [5]. The range of clinical
manifestations is diverse, involving multiple body systems with
a predominance of the central nervous system [6,7]. Clinical
and laboratory ﬁndings that suggest an organic acidemia in-
clude acidosis, ketosis, hyperammonemia, abnormal liver func-
tion tests, hypoglycemia, and neutropenia [8]. The diagnosis is
usually made by detecting an abnormal pattern of organic
acids in a urine sample by gas chromatography–mass spec-
trometry (GC/MS) [9–11].
In GC/MS screening, organic acids are separated on the ba-
sis of their polarity and volatility and then bombarded by an
electron beam that fragments the eluting molecules in a pattern
characteristic of each organic acid. However, the organic acids
must ﬁrst be extracted from the urine sample and then chemi-
cally modiﬁed to make the organic acids sufﬁciently volatile
before GC/MS analysis [12].
Another technique for organic acid analysis in urine is the
isocratic ‘‘high-performance liquid chromatographic’’ (HPLC)
technique has been developed. This depends on spectrophoto-
metric and amperometric detection after combined reversed-
phase and cation-exchange chromatography [13]. Advantages
of this technique over conventional gas chromatography in-
clude, ease of sample preparation and the simultaneous detec-
tion of non-volatile fatty acids. Limitations include; its lack of
sensitive identiﬁcation system comparable to that of mass spec-
trometry, the presence of non-ultraviolet absorbing fatty acids
and the relatively long retention times of phenolic compounds
[9,13].
The urinary organic acid proﬁle is abnormal in the face of
any illness with decompensation; however, in some disorders
diagnostic analytes may be present only in small or barely
detectable amounts when the affected individual is not acutely
ill. A plasma or serum acylcarnitine proﬁle by liquid chroma-
tography–tandem mass spectrometry (LC–MS/MS) can alsoprovide a rapid clue to the diagnosis [12]. Urine acylcarnitine
proﬁling is more complex and interpretation can be difﬁcult
[14].
Depending on the speciﬁc disorder, plasma amino acid
analysis using a quantitative method such as column chroma-
tography, high-performance liquid chromatography (HPLC),
or GC/MS can also be helpful. Conﬁrmatory testing involves
assay of the activity of the deﬁcient enzyme in lymphocytes
or cultured ﬁbroblasts and/or molecular genetic testing may
also be needed [15].
This study was aimed to evaluate the use of the HPLC
method to screen for disease associated-metabolites and com-
pare its speciﬁcity and sensitivity with GC/MS for patients
with organic acidemias and several other IEMs by tandem
mass spectrometry, gas chromatography–mass spectrometry,
and isocratic high performance liquid chromatography.
2. Patients and specimens
A total of 103 Egyptian patients, aged from 3 days to 12 years
old, who were admitted to theMedical Genetics Unit of the Ain
Shams University, Pediatrics Hospital, Cairo, Egypt from June
15th 2010 to February 25th 2013 and suffering from any of in-
born error metabolic disorder were subjected to the screening
study. They were divided into two groups. Group 1 with 86
patients (47 males and 39 females) who were suspected of
having an organic acid disorder; it was subsequently divided
into sub-groups according to their ﬁnal diagnosis as shown in
(Table 1).
Group 2 was 17 urine samples (12 males and 5 females)
from patients who were diagnosed with different other IEMs
(Table 2). Moreover, a control group of 24 urine samples from
healthy subjects, aged from 3 days to 10 years (7 samples from
newborns <1 month old, 6 samples from infants between 1
and 12 months old, and 11 samples from healthy controls be-
tween 1 and 10 years old.), was tested by HPLC to determine
the reference ranges for all organic acids found in normal urine
samples. Organic acid calibrators were prepared in water at
concentrations of 1000, 500 and 100 mg/dl for several standard
organic acids (Sigma chemical Co. Ltd., Poole, Dorset, U.K.)
that are possibly found in normal and metabolically disturbed
urine samples (Table 3).
Urine specimens from all studied patients were collected in
plastic laboratory containers and frozen immediately at
20 C until analysis by HPLC. Another urine sample from
the 86 patients suspected with organic acid disorders was col-
lected for GC/MS analysis. Urine samples from neonates and
Table 3 Retention times of organic acids found in normal and
abnormal urinary HPLC chromatograms.
ID Organic acid Mean RT (min) ± SD
1 Miscellaneous 5.40 ± 0.05
2 Oxalic acid 6.31 ± 0.06
3 Methylcitric acid 6.89 ± 0.06
4 3-Hydroxyglutaric acid 6.94 ± 0.18
5 Pyruvic acid 7.52 ± 0.11
6 2-Keto-3-methylvaleric acid 8.01 ± 0.02
7 Unknown 8.56 ± 0.08
8 Propionylglycine 8.58 ± 0.01
9 Methylmalonic acid 8.60 ± 0.06
10 2-Ketoisocaproic acid 8.68 ± 0.01
11 Succinic acid 9.83 ± 0.26
12 3-Hydroxyproponic acid 9.98 ± 0.21
13 Lactic acid 10.19 ± 0.09
14 3-hydroxybutyric acid 10.32 ± 0.10
15 2-Methyl-3-hydroxybutyric acid 10.32 ± 0.02
16 3-Hydroxyisovaleric acid 10.63 ± 0.04
17 2-Hydroxyisovaleric acid 10.74 ± 0.03
18 2-Methylacetoacetic acid 10.85 ± 0.06
19 Glutaric acid 11.16 ± 0.20
20 Uric acid 12.36 ± 0.07
21 Propionic acid 13.37 ± 0.26
22 Isovalerylglycine 13.75 ± 0.01
23 Pyroglutamic acid 13.96 ± 0.08
24 Unknown 15.51 ± 0.10
25 Unknown 16.62 ± 0.25
26 Tiglylglycine 18.49 ± 0.49
27 Unknown 21.94 ± 0.75
28 Unknown 24.88 ± 0.15
29 Unknown 28.30 ± 0.15
30 Unknown 30.63 ± 0.49
31 Hippuric acid 33.62 ± 0.19
32 Unknown 38.69 ± 0.21
33 Unknown 45.87 ± 0.11
3-phenylpropionic acid (internal standard) 75 ± 0.06
Peaks that are diagnostically signiﬁcant were represented in bold,
while many normal peaks remained unidentiﬁed.
Table 1 Patient groups and subgroups.
Patients suspected with organic acid disorder (N= 86)
Subgroup No. of Patients Sex
Male Female
1 Methylmalonic aciduria 15 8 7
2 Glutaric aciduria type 1 9 8 1
3 Isovaleric aciduria 2 0 2
4 Propionic aciduria 2 1 1
5 b-ketothiolase deﬁciency 1 1 0
6 Pyroglutamic aciduria 1 1 0
7 Maple syrup urine disease 2 2 0
8 Lactic acidosis 1 0 1
9 Questionable 9 6 3
10 Normal 44 20 24
Total 86 47 39
Table 2 Subgroups of patients with IEMs.
Patients with diﬀerent IEMs (N= 17)
Subgroup No. of Patients Sex
Male Female
1 Urea cycle defects 3 2 1
2 Mitochondrial disorders 9 6 3
3 Creatine deﬁciency 1 1 0
4 Non-ketotic hyperglycinemia 2 2 0
5 Dicarboxylic aciduria 1 0 1
6 Hyperoxaluria 1 1 0
Total 17 12 5
Screening of diseases associated with abnormal metabolites for evaluation of HPLC 71infants were collected in special sterile plastic bags then trans-
ferred into urine containers.
The work has been carried out in accordance with the code
of ethics of the World Medical Association (Declaration of
Helsinki) for experiments involving humans. The work was
carried out after the acceptance of parents of the patients
and acceptance of the Ethics Committee of the University.
3. Methods
3.1. Isocratic cation exchange ‘‘high-performance liquid-
chromatography’’ (HPLC)
The technique was previously reported by Bannett and Bradey
[13] for the determination of organic acids in urine.
3.1.1. Equipments and reagents
The HPLC equipment (supplied by Bio-Rad, Richmond, CA)
consisted of a Model 2700T solvent delivery system, a D8I
injector, a Model 450 wavelength detector and a Phenomenex
cation-exchange column maintained in a constant temperature
at 37 C, the solvent was H2SO4, 0.25 ml/L, with a ﬂow rate
1 ml/min and the detecting wavelength was set at 210 nm.
3.1.2. Chromatography
Urine samples were ﬁltered through 0.22 lm Millipore ﬁlter
(Sartorius Stedim Biotech., Geottingen, Germany), related to
creatinine concentration (injected volume was 10 ll if
creatinine concentration <0.02 mg/dl and a volume of 5 ll ifcreatinine concentration >0.02 mg/dl) and mixed with
3-phenylpropionic acid as an internal standard before injecting
it onto the column. The average chromatographic analysis
time for urine was 1.5 h.
3.2. Gas-chromatography mass spectrometry (GC/MS)
GC/MS was done in another laboratory to study urinary or-
ganic acid patterns by gas chromatography–mass spectrometry
using GC/MS (Agilent Technologies Inc., QP2010). Sample
preparation and detection procedures were based on methods
reported previously by Kuhara [19].3.3. Acylcarnitines and amino acids proﬁling by liquid
chromatography–tandem mass spectrometry (LC–MS/MS)
A rapid metabolic screening technique is the analysis of
acylcarnitine proﬁles in dried blood spots by tandem quadru-
pole mass spectrometry (ACQUITY UPLC System, Waters
associates, Northwich, Cheshire, UK) [16]. Blood samples
72 D.A. Ghoraba et al.were taken from the patients by heelstick, spotted on What-
man ﬁlter paper cards (Schleicher and Schuell 903; Dassel,
Germany) and left to dry before screening by tandem mass
spectrometry.
Sample preparation and detection procedures were based
on methods reported previously [17,18]. Acylcarnitines were
automatically calculated according to the assigned values of
the internal standards using Math Lynx software. Quality
control samples were provided by the Center for Disease Con-
trol and Prevention, Atlanta, GA, USA.Figure 1 Typical chromatogram of urine from a normal
neonate. Peak 26 represents tiglylglycine [18.49 ± 0.49] was also
detected in normal chromatograms.
Table 4 Quantitative determination of urinary MMA level in
ﬁve newly diagnosed mut-MMA patients by the HPLC
technique.
Patient no. MMA (mg/dl) Urinary Cra (mg/dl) MMA mg/mg Cr
2 972 23 42,260
3 681.8 8 85,225
5 1119 33 33,909
8 104.5 23 4543
9 449 128 3507
a Urinary creatinine.3.3.1. Statistical analysis
Data acquired from the patients suspected with organic acid
disorders (N= 86) were statistically analyzed by cross tabula-
tion, chi square test and Z-test between two proportions [20].
Cross tabulation and chi square test were used to test the accu-
racy of HPLC, GC–MS and tandem mass spectrometry in the
diagnosis of the patients suspected with organic acid disorder.
Z-test between two proportions was used to compare between
HPLC and GC–MS as screening tools for urinary organic
acids. Scores were given to indicate the precision of testing
as follows;
1 = Results are the same as the ﬁnal diagnosis,
2 = Results are inconclusive (not diagnostic but support
the ﬁnal diagnosis),
3 = Questionable (unknown abnormality or no ﬁnal
diagnosis),
4 =Wrong diagnosis or false negative.
4. Results
Out of 86 cases, We had nine questionable cases: Two pa-
tients (11 and 12), a brother and his sister, had consistently
elevated level of C4DC (C4-dicarboxylic or methylmalonic/
succinyl-carnitine) upon LC–MS/MS screening, intermit-
tently elevated methylmalonic acid in GC/MS screening
and mildly elevated methylmalonic acid in HPLC screening
and other HPLC urinary organic acids proﬁle abnormalities.
Differential diagnosis suggested methylmalonic aciduria
(MMA) due to succinyl CoA ligase deﬁciency. However,
no enzyme assay was available to prove the diagnosis. Other
two patients were questionable upon GC/MS and HPLC
screenings with elevated non-diagnostic urinary organic acids
and were normal in metabolic screening by tandem mass
spectrometry. We lost follow up of other ﬁve questionable
cases and ﬁnal diagnosis was not deﬁnitely determined
made.4.1. Normal urine pattern by HPLC
All chromatograms of normal control group showed that urea
and uric acid usually were the major peaks (Fig. 1), other smal-
ler peaks, all of them less than 20% of the size of uric acid
peak, include; succinic, 3-hydroxybutyric, oxalic and hippuric
acids which were detected in virtually all tested urine samples.
Methylmalonic acid was detected in trace amount, which does
not exceed 5 mmol/mol Cr, tiglylglycine and many other smal-
ler unidentiﬁed peaks in normal urine samples.Retention times of organic acids detected in normal and
abnormal urinary HPLC chromatograms are presented in
Table 4. Organic acids are listed, starting from 1 (represents
urea, creatinine, proprandiol and sulfate) to 34 (represents
the internal standard), in order of their retention times [mean
retention time (min) ± SD] to observe their recurrence in dif-
ferent samples.
4.2. Metabolic Proﬁling of samples with organic acid disorders
The initial screening of organic acids in urine, using HPLC
method, has helped in many ways in the initial assessment
and follow up of patients with different types of organic acid-
urias. The chromatograms of urine samples from several pa-
tients with organic acid disorders are presented in (Figs. 2–8)
to help the investigator who is going to start an organic acid
screening program by HPLC become familiar with various
patterns. Peaks that are diagnostic for the diseases are very
large compared with others.
Two different proﬁles of methylmalonic academia (MMA)
patients (Fig. 2A) have shown an abnormal peak correspond-
ing to MMA, in addition, smaller peaks of metabolites from
isoleucine, such as tiglylglycine, and the secondary metabolites
of propionate (3-hydroxypropionic and methylcitric acids).
Concentration of urinary methylmalonic acid/creatinine
(MMA/Cr) was quantitatively estimated by HPLC for patients
Figure 2 Urinary organic acids from patients with methylmalonic aciduria diagnostic peaks are: 3, methylcitric acid [6.89 ± 0.06]; 9,
methylmalonic acid [8.60 ± 0.06]; 12, 3-hydroxyproponic acid [9.98 ± 0.21]. (A) Untreated methylmalonicaciduria patients showed
highly elevated MMA, methylcitric acid and 3-hydroxypropionic acid. (B) Diet controlled MMA patient; An abnormal peak
corresponding to hippuric acid can be seen, along with a smaller peak of methylmalonic acid.
Figure 3 Urinary organic acids from a patient with propionic aciduria diagnostic peaks are: 3, methylcitric acid [6.89 ± 0.06]; 8,
propionylglycine [8.58 ± 0.01]; 12, 3-hydroxyproponic acid [9.98 ± 0.21]; 13, lactic acid [10.19 ± 0.09]; 14, 3-hydroxybutyric acid
[10.32 ± 0.10]; 16, 3-hydroxyisovaleric acid [10.63 ± 0.04]; 18, 2-methylacetoacetic acid [10.85 ± 0.06]; 21, propionic acid [13.37 ± 0.26];
26, tiglylglycine [18.49 ± 0.49].
Screening of diseases associated with abnormal metabolites for evaluation of HPLC 732, 3, 5, 8 and 9 at the onset of the symptoms, where MMA was
signiﬁcantly elevated (up to 2000 mg/mg of creatinine) and eas-ily detected in urine (Table 4). MMA level in urine has been
completely normalized with treatment as shown in Fig. 2B,
Figure 4 Urinary organic acids from a patient with glutaric
aciduria type I diagnostic peaks are: 4, 3-hydroxyglutaric acid
[6.94 ± 0.18]; 13, lactic acid [10.19 ± 0.19]; 19, glutaric acid
[11.16 ± 0.20].
Figure 7 Urinary organic acids from a patient with pyroglu-
tamic aciduria diagnostic peaks are: 13, lactic acid [10.19 ± 0.09];
23, pyroglutamic acid [13.96 ± 0.08].
Figure 8 Urinary organic acids from a patient with maple syrup
urine disease (MSUD) diagnostic peaks are: 5, pyruvic acid
[7.52 ± 0.11]; 6, 2-keto-3-methylvaleric acid [8.01 ± 0.02]; 10, 2-
ketoisocaproic acid [8.68 ± 1]; [16, lactic acid [10.19 ± 0.09]; 17,
2-hydroxyisovaleric acid [10.59 ± 0.02].
Figure 5 Urinary organic acids from a patient with isovaleric
aciduria diagnostic peaks are: 16, 3-hydroxyisovaleric acid
[10.63 ± 0.04]; 22, isovalerylglycine [13.75 ± 0.01].
Figure 6 Urinary organic acids from a patient with b-ketothi-
olase deﬁciency diagnostic peaks are: 15, 2-methyl-3-hydroxybu-
tyric acid [10.32 ± 0.02]; 18, 2-methylacetoacetic acid
[10.85 ± 0.06].
74 D.A. Ghoraba et al.where hippuric acid can be seen along with a smaller peak of
methylmalonic acid. We reported propionic academia (PA)
(Fig. 3A before and B after management) in two patients,
where the lower 3-hydroxypropionic acid level could charac-
terize the ketoacidotic state proﬁle of PA from multiple car-
boxylase deﬁciency (MCD). Elevated levels of speciﬁc
organic acids were diagnostically signiﬁcant in the initial
urinary organic acids screening by HPLC, as glutaric and
3-hydroxy-glutaric acids in glutaric aciduria type I (GA1)
(which were remarkably elevated in all patients) (Fig. 4),
3-hydroxyisovaleric acid in patients with isovaleric aciduria
(IVA) (Fig. 5), 2-methyl-3-hydroxybutyric and 2-methylaceto-
acetic acids in patients with b-ketothiolase deﬁciency (BKT)
(Fig. 6), and pyroglutamic acid in a patient with pyroglutamic
aciduria (Fig. 7).
Multiple urinary organic acid abnormalities reported by
HPLC for maple syrup urine disease (MSUD) patients, who
were diagnosed by LC–MS/MS, included pyruvic, 2-keto-3-
methylvaleric, 2-ketoisocaproic, lactic and 2-hydroxyisovaleric
acids (Fig. 8).
Figure 11 Hyperoxaluria diagnostic peak is oxalic acid
[6.31 ± 0.06].
Screening of diseases associated with abnormal metabolites for evaluation of HPLC 75Organic acids were identical to those detected with GC/MS
for all organic acid disorders. Acylcarnitines and amino acids
proﬁling by tandem mass spectrometry would be more applica-
ble for rapid diagnosis of MSUD (by elevated Leu:Ile, Leu:
Ala, Leu:Phe and Valine), IVA (by elevated Isovalerylcarnitine
C5), GA1 (by elevated Glutarylcarnitine C5-DC), Inconclusive
for MMA, PA (with elevation of both Propionylcarnitine C3
and propionylcarnitine/acetylcarnitine C3:C2), BKT (with ele-
vated 2-methyl, and 3-hydroxybutyrylcarnitine C5-OH) and
not diagnostic in cases with pyroglutamic aciduria and lactic
acidosis (with falsely negative results).
4.3. Urine samples from patients with IEMs other than organic
acidemia
Among the 17 patients with IEMs other than organic acidemia
(Table 1), HPLC has detected abnormal urinary organic acid
proﬁles in patients 1–3 with urea cycle defects (where lactic
and pyruvic acids were signiﬁcantly elevated) (Fig. 9) and in
mitochondrial disorders cases, patients from 9 to 17, (where
elevated lactic and/or pyruvic acids, and either glutaric or 3-
hydroxyglutaric acid has been detected (Fig. 10)). Abnormal
proﬁles have been detected by HPLC in cases of creatineFigure 9 Urinary organic acids from a patient with lactic and
pyruvic acidurias diagnostic peaks are: 5, pyruvic acid
[7.52 ± 0.11]; 13, lactic acid [10.19 ± 0.09].
Figure 10 Query mitochondrial disorder diagnostic peaks are:
13, lactic acid [10.19 ± 0.09], 19, glutaric acid [11.16 ± 0.20].
Figure 12 Dicarboxylicaciduria diagnostic peaks are dicarbox-
ylic acid [7.02] and 4-hydroxyphenyllactic acid.deﬁciency, hyperoxaluria (Fig. 11) and dicarboxylicaciduria
(Fig. 12), while abnormalities have not been detected by HPLC
in cases of non-ketotic hyperglycinemia.
4.3.1. Statistical analysis
Table 5 presents the results of comparison between the three
methods by cross tabulation and the chi square test. There is
a statistically signiﬁcant difference between the three methods
(X2 = 54.206, p< 0.001). The highest and best accuracy was
reported with GC–MS (88.5%) in the diagnosis of organic
acidurias compared to the other two methods. HPLC had
the highest questionable results (18.1%) while LC–MS/MS
gave the highest inconclusive results (22.4%).
Table 6 presents the comparison between HPLC and
GC/MS in group 1 screening results. It showed higher sensitiv-
ity (92%) and predictive power for negative results (92%) of
HPLC compared to GC–MS that showed higher speciﬁcity
(100%) and predictive value of positive results (100%).5. Discussion
This study highlights some important aspects of testing, devel-
oping and validating an isocratic cation exchange HPLC meth-
od for qualitative analyses of urine samples from neonates and
infants suspected of having organic aciduria and other meta-
bolic disorders. We subjected a group of 86 urine samples of
Table 5 Accuracy of the result in the three methods in specimens of patients suspected with organic acid disorders.
Precision in group 1 Metabolic Screen GC/MS HPLC Chi square p-Value
No. % No % No %
Results are the same as the ﬁnal diagnosis 52 61.2 69 88.5 63 75.9 54.206 <0.001
Inconclusive (not suﬃcient for ﬁnal diagnosis) 19 22.4 0 0 0 0
Questionable (abnormal but unknown diagnosis) 7 8.2 2 2.6 15 18.1
False negative or wrong diagnosis 7 8.2 7 9 5 6
Total 85 100 78 100 83 100
Regarding accuracy, there is a statistical signiﬁcance between the three methods, GC/MS had the highest accurate results compared to other
methods. Inconclusive results were more with metabolic screening while HPLC had the highest questionable results.
Table 6 HPLC versus GC–MS in organic acid disorder patients.
Group 1: Organic acidurias HPLC GC/MS
Positive Negative Total Positive Negative Total
Criterion Positive 36 3 39 32 6 38
Negative 8 36 44 0 42 42
Total 44 39 83 32 48 80
Index HPLC GC/MS z P-Value
Estimate SE Lower 95% CI Upper 95% CI Estimate SE Lower 95% CI Upper 95% CI
Sensitivity 0.9231 0.0427 0.7913 0.9838 0.8421 0.0592 0.6875 0.9398 1.5727 >0.05
Speciﬁcity 0.8182 0.0581 0.6729 0.9181 1 0 0.9159 1 4.7088 <0.01
Predictive value of
positive test
0.8182 0.0581 0.6729 0.9181 1 0 0.8911 1 5.0015 <0.01
Predictive value of
negative test
0.9231 0.0427 0.7913 0.9838 0.875 0.0477 0.7475 0.9527 0.969 >0.05
There are statistically signiﬁcant differences between the results of the two methods regarding speciﬁcity and predictive value of positive test.
GC/MS had higher speciﬁcity and predictive power for positive test compared to HPLC method.
76 D.A. Ghoraba et al.Egyptian patients suspected with organic acid disorders, aged
from 1 day to 12 years of life, to the screening programs
by liquid chromatography–tandem mass spectrometry
(LC–MS/MS), gas chromatography–mass spectrometry
(GC–MS) and cation exchange isocratic ‘‘high-performance li-
quid-chromatography’’ (HPLC).
In all of the normal chromatograms we obtained by HPLC
in this study, the major identiﬁable peak was uric acid, which
matches with the ﬁnding reported by Bannett and Bradey [13].
Other peaks identiﬁed in normal urine samples, all of them less
than 20% of the size of uric acid, were hippuric and oxalic
acids, which were detected in virtually all tested urine samples
(Fig. 1). A ﬂattened peak of succinic acid and 3-hydroxybu-
tyric acid has also been detected in normal urine samples that
may be misinterpreted as lactic acid [13].
Methylmalonic acid detected in trace amount due to bacte-
rial growth does not exceed 5 mmol/mol Cr, but in cases of uri-
nary tract infection it was confusing to characterize the normally
from abnormally elevatedMMA in urine [21]. Therefore, an ap-
proach for the quantitative detection of methylmalonic acid in
urine has been done in this study for patients 2, 3, 5, 8 and 9
at the onset of the symptoms, whereMMAwas signiﬁcantly ele-
vated (up to 2000 mg/mg of creatinine) and easily detected in ur-
ine. Tiglylglycine was also reported in the majority of normal
chromatograms as reported by Bennett et al. [22].We presented some typical urinary HPLC chromatograms
of different metabolic disorders to help the investigator who
is going to start an organic aciduria screening program by
HPLC become familiar with various patterns. The results
showed that this method is useful as an initial screening tool
of organic acids in urine samples of neonates and infants,
where it can detect any abnormalities of organic acids in urine.
Although the identity of metabolites in these urine samples was
later conﬁrmed by GC/MS analysis, the initial identiﬁcation
was done by HPLC alone, with the use of the table of retention
time values (Table 3) of recalibrated organic acids of those re-
ported by Bannett and Bradey [13].
Patients with methylmalonic aciduria showed elevated
methylmalnic, methylcitric and 3-hydroxypropionic acids
(which lies in the same retention times of lactic and 3-hydroxy-
butyric acids). Sometimes propionic, fumaric and lactic acids
were also detected. Elevated C4-dicarboxylic carnitine may
contribute to the diagnosis of methylamalonic aciduria due
to succinyl CoA ligase deﬁciency as reported in this study in
patients 11 and 12. We detected the same pattern in patients
with propionic acidemia except normal MMA level which
could be distinguished in propionic acidemia patients. Patients
with glutaric aciduria type 1 have shown elevated glutaric acid
and 3-hydroxyglutaric acid. Diagnosis of isovaleric aciduria
was not conclusive with the detection of 3-hydroxyisovaleric
Screening of diseases associated with abnormal metabolites for evaluation of HPLC 77acid and isovalerylglycine and absence of isovaleric acid in
most cases. Abnormalities were reported by Bannett and
Bradey [13] in patients with b-ketothiolase deﬁciency as
unidentiﬁed peaks, which were identiﬁed in this study as
2-methyl-3-hydroxybutyric and 2-methylacetoacetic acids.
We also identiﬁed other diagnostic peaks for different meta-
bolic disorders as pyroglutamic acid in pyroglutamic aciduria
which tested normal via acylcarnitines proﬁling, pyruvic acid,
2-keto-3-methylvaleric acid, 2-ketoisocaproic acid, lactic acid
and 2-hydroxyisovaleric acid in maple syrup urine disease
(MSUD) but screening by LC–MS/MS would be more reliable
for this disorder.
Data obtained from the three methods, LC–MS/MS,
GC–MS and HPLC, showed varied diagnostic power among
the two tested groups. Statistical analyses showed higher sensi-
tivity (92%) and positive power in detecting negative results
(92%) toHPLCcompared toGC–MS. It also showed the lowest
accuracy in diagnosis (75%) and the highest score in detecting
urinary organic acids proﬁle abnormalities (76.5%). This means
that we can rely on HPLC in detecting urinary organic acid
abnormalities but the results will not be conclusive in the
diagnosis.
In this study also, we tested about 17 patients with different
IEMs to test the power of HPLC to detect normal urine sam-
ples. Although a chromatogram from a patient with gross
dicarboxylic aciduria did not appear to be as abnormal as the
corresponding GC/MS proﬁle with glycerol detection, results
were abnormal to a great extent in most cases as the detection
of lactic and pyruvic acids in urea cycle defect (UCD) (adipic
and orotic acids only detected GC/MS) and different mito-
chondrial disorders, glutaric, 3-hydroxyglutaric and lactic acids
in some mitochondrial disorders, oxalic acid in the case of
hyperoxaluria, while abnormalities have not been detected by
HPLC in cases of non-ketotic hyperglycinemia. This means
that, in most cases of metabolic disorders, HPLC can exclude
normal and abnormal urinary organic acid proﬁles effectively.
However, some abnormalities detected by HPLC chro-
matograms may be an indicative for a pathophysiological ill-
ness as 4-hydroxyphenyllactic acid showed in patients with
liver dysfunction.
Limitations include the inability to distinguish between iso-
mers such as lactic acid, succinic acid and 3-hydroxypropionic
acid and the lack of an identiﬁcation system since one peak
may indicate more than one organic acid which lies within clo-
sely the same retention time.
To conclude HPLC method is fast, inexpensive and easier
in sample preparations compared to GC/MS [19] and LC–
MS/MS [14,16]. It is also more easily applicable to routine
analysis in non-specialized laboratories and a useful technique
not only for initial screening of organic acid disorders but also
of many other metabolic disorders.
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